Investor presentations
Webcast - update from the ODAC meeting, Sep 22
September 23, 2022
September 23, 2022, the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto® (melphalan flufena...
Webcast - presentation of the Q2 Interim Report 2022
August 9, 2022
Oncopeptides published its report for the second quarter 2022 on August 11, 2022, and hosted a webcast on the same day at 14:00 CET.
Webcast - CHMP rekommenderar att Oncopeptides Pepaxti får ett fullt godkännande i EU
June 23, 2022
June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization appro...
How do you manage expectations and communicate setbacks as a small, listed biotech company? - CEO sitdown with Jakob
June 1, 2022
CEO Jakob Lindberg took part in a webcast called CEO sitdown at Paues Åberg June 1, 2022. The interview is moderated by Caroline Wiken, partner at Paues Åberg.
ABGSC Life Science Summit 2022
May 19, 2022
Oncopeptides CEO Jakob Lindberg presented at the ABGSC Life Science Summit 2022, May 19.
Carnegie Healthcare Seminar 2022
March 17, 2022
Oncopeptides CEO Jakob Lindberg presented at Carnegie Healthcare Seminar 2022, March 17 at 16.45 CET. See the presentation below.
Webcast - Presentation of the Year-end Report 2021
February 14, 2022
Oncopeptides published its report for the fourth quarter and year-end results 2021 on February 17, 2022, and hosted a webcast on the same day at 15:00 CET.
Webcast - Oncopeptides rescinds voluntary withdrawal of Pepaxto
January 21, 2022
January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pep...
Webcast - Presentation of the Q3 Interim Report 2021
November 19, 2021
Oncopeptides published its report for the third quarter 2021 on November 24, 2021, and hosted a webcast on the same day at 10:00 CET.
Webcast - Oncopeptides withdraw Pepaxto® in US, scale down organization and focus on R&D
October 22, 2021
October 22, 2021, Oncopeptides announced that the company has decided to withdraw Pepaxto® from the market in the US. The decision has been made after interactions and dialogue with the US Food and Dr...
Handelsbanken Healthy Hour - presentation
September 15, 2021
Oncopeptides presented at Handelsbanken Healthy Hour on September 15. The presentation was held by CEO Marty J Duvall, CSO Klaas Bakker and CFO Anders Martin-Löf.
Webcast for presentation of OCEAN data presented at IMW
September 9, 2021
Oncopeptides presented data from the OCEAN study at the 18th International Myeloma Workshop (IMW) on September 11. Investors, financial analysts, and media were invited to participate in a webcast inc...
Presentation of the Q2 Interim Report 2021
August 12, 2021
Oncopeptides has published its report for the second quarter 2021 on August 19, 2021, and hosted a webcast on the same day at 12:00 CEST.
Presentation updated OCEAN data
July 8, 2021
Oncopeptides hosted a webcast on July 8, 2021, at 11:00 (CET) including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, and CMO Klaas Bakker.
Redeye Growth Day 2021 presentation
June 2, 2021
Oncopeptides' CFO Anders Martin-Löf presented at Redeye Growth Day 2021 , June 2.
Presentation of the Q1 Interim Report 2021
May 26, 2021
Oncopeptides has published the Q1 Interim Report 2021 and hosted a webcast the same day at 12:00 (CET), May 26, 2021.
Webcast - presentation of OCEAN topline data, May 25, 2021
May 25, 2021
In conjunction with the release of the topline data of the OCEAN study, Oncopeptides hosted a webcast May 25, 2021, at 11:00 (CET), including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, C...
Theme Day Commercialization of Medicine - Erik Penser Bank
May 6, 2021
Oncopeptides's CFO Anders Martin-Löf presented at Erik Penser Bank's theme day Commercialization of medical component on May 6 at 16:15 CET. The theme day was broadcasted live 09:00-17:00 CET. Welcome...
Aktiedagen Stockholm - Aktiespararna
May 4, 2021
Oncopeptides's CFO Anders Martin-Löf presented at Aktiespararna's event Aktiedagen Stockholm on May 4 at 13:30 CET. The share day was broadcasted live from 07: 50-20:00 CET and 18 listed companies par...
Cowen 41st Annual Health Care Conference - presentation
March 3, 2021
Oncopeptides' CEO Marty J Duvall presented at the Cowen 41st Annual Health Care Conference, March 3, 2021, at 17.00 CET. The presenation is webcasted, see link below.
Company Presentation March 2021
March 3, 2021
New Company Presentation for Oncopeptides, March 2021.
FDA approval of PEPAXTO - Webcast for investors, analysts and the media
March 1, 2021
In conjunction with the FDA approval of PEPAXTO February 26, Oncopeptides hosted a webcast March 1, 2021, at 07:30 (CET), including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas B...
Webcast Year-end Report 2020 presentation
February 18, 2021
Oncopeptides held a webcast February 18, 2021 at 14:00 (CET) when the Year-end Report 2020 and an operational update was presented by CEO Marty J Duvall, CMO Klaas Bakker and CFO Anders Martin-Löf.
Oncopeptides Virtual Capital Markets Day
November 30, 2020
“Building a Fully Integrated Biotechnology Company”
Jefferies London Health Care Conference presentation
November 18, 2020
Marty J Duvall presents at Jefferies London Health Care Conference, Wednesday December 18, 2020. The webcast is recorded. See presentation and link below.
Citi’s 15th Annual BioPharma Virtual Conference – Presentation
September 10, 2020
Oncopeptides' CEO Marty J Duvall and CSO Jakob Lindberg presented at Citi’s 15th Annual BioPharma Virtual Conference. Please see attached presentation below.
Pareto Securities 11:e Healthcare Conference – Presentation
September 2, 2020
Oncopeptides' CEO Marty J Duvall and CSO Jakob Lindberg presented at Pareto Securities Healthcare Conference. Please see attached presentation.
Webcast regarding operational update Q2 2020
August 26, 2020
Oncopeptides held an operational update Wednesday August 26, 2020. It was presented by CEO Marty J Duvall, CSO Jakob Lindberg and CFO Anders Martin-Löf. The presentation was also recorded, see link be...
Nordea Small Cap Seminar – Presentation
August 12, 2020
Oncopeptides presented at Nordea Small Cap Seminar on Aug 12, 2020. See presentation below.
Jefferies Healthcare Conference June 3, 2020
June 3, 2020
Oncopeptides CEO presents at 1.30 – 1.55 PM (EDT) (19.30-19.55 CEST). See attached presentation, and click the link below to come to the webinar.
Webcast regarding operational update Q1 2020
May 26, 2020
Oncopeptides held an operational update Tuesday May 26, 2020. It was presented by CEO Jakob Lindberg and members of Oncopeptides management team. The presentation was recorded, see link below.
Stockholm Corporate Finance Life Science Day – presentation
March 11, 2020
Oncopeptides’ CFO Anders Martin-Löf presented at the Stockholm Corporate Finance Life Science Day, March 11, 2020. See the recording of the presentation, and the presentation below.
2020 J.P. Morgan Health Care Conference – Presentation
January 21, 2020
San Francisco, 13-16 January 2020
Avanza Lunch Presentation
November 27, 2019
Oncopeptides’ CEO Jakob Lindberg presented at the Avanza Lunch meeting.
Investing in Oncology Forum 2019
October 7, 2019
Oncopeptides’ CFO Anders Martin-Löf held a presentation at Investing in Oncology Forum 2019 in Stockholm, Sweden, on October 7.
Pareto Health Care Conference 2019
September 5, 2019
Oncopeptides AB (publ) presented at the Pareto Securities Health Care Conference 2019. See attached presentation.
REDEYE Growth Day – Presentation
June 10, 2019
Oncopeptides CFO Anders Martin-Löf held a presentation at the REDEYE Growth Day, 10 June 2019. The Presentation was recorded and can be showed at the link below.
Jefferies 2019 Healthcare Conference, New York – Presentation
June 5, 2019
Oncopeptides CEO Jakob Lindberg gave a presentation at Jefferies Healthcare Conference in New York June 7, at 17.30 CET. The presentation was webcasted, see link below. You can also listen to the pres...
REDEYE Pre-ASCO Seminar – presentation
May 28, 2019
CEO Jakob Lindberg presented at the REDEYE Pre-ASCO Seminar, Tuesday May 28, in Stockholm, Sweden. See link to the recording of the presentation below.
Webcast regarding operational update
May 21, 2019
Oncopeptides held an operational update on Tuesday, May 21, 2019, at. 10:00 (CET). It was presented by CEO Jakob Lindberg and members of the Oncopeptides management team. The webcast was recorded. See...
Webcast regarding clinical program update
April 24, 2019
Oncopeptides held an webcast April 24, 2019, where CEO Jakob Lindberg provided new guidance on the patient recruitment in the OCEAN study and a clinical program update. The webcast was recorded. See t...
Kempen Life Science Conference 2019 – presentation
April 16, 2019
Oncopeptides presented at the Kempen Life Science Conference 2019 in Amsterdam, Netherlands.
Cowen & Company 39th Annual Health Care Conference – Presentation
March 11, 2019
CEO Jakob Lindberg presented at Cowen and Company 39th Annual Health Care Conference on March 11, 2019. The presentation was webbcasted, see link below.
Carnegie Healthcare Conference 2019 – presentation
March 6, 2019
CEO Jakob Lindberg presented at Carnegie Healthcare Conference, on March 6 2019.
Webcast Year-End Report 2018
February 22, 2019
The Year-end Report for 2018 and an operational update was presented by CEO Jakob Lindberg and members of Oncopeptides management team, February 22, 2019 at 14:00 (CET).
SEB Biotech Seminar – presentation
January 24, 2019
By Jakob Lindberg, CEO, Oncopeptides AB (publ).
2019 J.P. Morgan Health Care Conference – Presentation
January 16, 2019
San Francisco, January 7-10, 2019.
Oncopeptides Capital Markets Day in New York – presentations
December 14, 2018
Oncopeptides did host a Capital Markets Day on December 14th between 8.30-11.00 AM ET in New York, here is the presentation from the whole day. Speakers were Jakob Lindberg, Chief Executive Officer, o...
DNB Nordic Healthcare Conference 2018 – presentation
December 13, 2018
December 12, CEO Jacob Lindberg held a presentation at the DNB Nordic Healthcare Conference 2018 in Oslo.
Jakob Lindberg, CEO, Oncopeptides – Company presentation post ASH
December 6, 2018
Jakob Lindberg, CEO, Oncopeptides – Company presentation post ASH 2018.
Jefferies 2018 London Healthcare conference – Presentation & webcast
November 14, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies 2018 Healthcare conference in London November 14. The presentation was also recorded. Click on the recording (mp3-file) to view the Web...
Lunch presentation at DNB
September 25, 2018
Corporate presentation by Jakob Lindberg, CEO, Oncopeptides AB (publ), at DNB 25 September 2018.
Jefferies Health Care conference, New York – Presentation
June 7, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies Healthcare Conference in New York June 7.
Carnegie Healthcare Seminar 2018 – presentation
March 14, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Carnegie Healthcare Seminar on March 14.
SCF Life Science Seminarium – presentation
March 7, 2018
Oncopeptides CEO Jakob Lindberg held a presentation at Stockholm Corporate Finance Live Science Seminarium March 7.
ABGSC Orphan Drug Day 2018 – Presentation
February 22, 2018
Oncopeptides presentation at the ABG Office in Stockholm, Sweden.
Jakob Lindberg interviewed in DI Börsmorgon
January 25, 2018
Oncopeptides CEO Jakob Lindberg is being interviewed in DI Börsmorgon, January 25, 2018.
DNB Nordic Healthcare Conference 2017 – Oslo
December 14, 2017
Oncopeptides’ presentation at DNB in Oslo, 14 December.
Carnegie Healthcare Day in New York – presentation
December 6, 2017
Oncopeptides presentation at Carnegie, New York, 5 December 2017.
Press release -
Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)
Read press release
Upcoming events
-
-
-
-
-
-
08:00 CET
Oncopeptides via e-mail
Get our latest updates straight to your inbox. Unsubscribe at anytime.